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Supplementary Methods  27 
1. Baseline review and horizon scan 28 
A baseline review and horizon scan was conducted across 60 areas of science, technology, health 29 
and regulatory science (Table S1). These areas were identified by the EMA’s Scientific Coordination 30 
Group (SCG), which includes the Agency’s scientific leadership. A first round of horizon scanning was 31 
undertaken by a multidisciplinary drafting/research group.  Internal databases, in addition to the 32 
scientific literature, were mined to provide an analysis of the state-of-the-art in each area, and the 33 
anticipated challenges and opportunities therein over the next 5-10 years.  Peer review of the results 34 
was performed sequentially, first within the research group, then by in-house specialists, and finally 35 
by the SCG. 36 
2. Stakeholder outreach  37 
To validate these internal findings, 55 semi-structured and 15 open interviews were conducted with 38 
external experts and key opinion leaders from the EMA’s principal stakeholder groups.  These 39 
individuals were nominated by the EMRN and selected from the Agency’s expert database; non-40 
response error was minimised by follow-up reminders to the participants.  Prior to the interviews, 41 
the participants were made aware that horizon-scanning had been performed beforehand but were 42 
only provided with the introduction to the baseline review and the interview questions.  The semi-43 
structured interviews were designed iteratively by: (a) brainstorming with colleagues to identify key 44 
questions, (b) alignment of these questions with the overarching goal of the regulatory science 45 
reflection, (c) trialling with colleagues, re-ordering and refining for optimisation of timing; (d) testing 46 
on a limited panel of interviewees, with initial feedback incorporated into a final interview format 47 
(Table S2) , and finally (e) adopting the core format appropriately tailored to the individual 48 
stakeholder groups interviewed.  During the open interviews, the semi-structured approach was 49 
followed only after the interviewee had set the initial topics for discussion.    50 
3. Data collection and analysis 51 
The duration of a semi-structured interview was typically about 1 hour; the open interviews were 52 
longer, up to 2 hours.  Notes of the interview were taken by two or more members of the research 53 
team and cross-checked for accuracy.  The interviews were not recorded, however.  The results were 54 
analysed using open and axial coding1,2 which involved independent review of the interview notes by 55 
the researchers and assignment of codes to meaningful sections of text (words, sentences and 56 
statements). These were then compared, and a sub-set agreed, before further rounds of axial 57 
coding.  Our findings are reported below (Table S3) using the Consolidated Criteria for Reporting 58 
Qualitative Research (COREQ)3.  The resulting themes and sub-themes were then mapped onto the 59 
outputs of the baseline review and horizon-scanning, and formed the basis of a draft set of 60 
regulatory science strategic goals, each comprising a series of core recommendations and underlying 61 
actions identified for their delivery.  62 
The draft collection of strategic goals, core recommendations and underlying actions (Table S3) was 63 
then reviewed and refined by the SCG and the EMA’s Scientific Coordination Board, which comprises 64 
the chairs of the Agency’s key committeesa.  Finally, this reflection was released at the workshop 65 
held at EMA on October 24, 2018, “EMA – Regulatory Science to 2025”, following which a 66 
consultation document detailing the summary outlined in this Comment was approved by the SCG 67 
and the Scientific Coordination Board for release and commentb. 68 
4. Interview questions to principal stakeholder groups 69 
(a) What are the top three science, technology and regulatory challenges and opportunities in your 70 
field of work? 71 
(b) Taking each of the three topics in turn, how will this impact clinical development, and then 72 
translation to clinical care? 73 
Example impacts on clinical development might include: candidate selection, pre-clinical development, 74 
biomarkers; costs – increased costs or savings; societal and legal issues - ethical issues, controversial method or 75 
highly invasive. 76 
Example impacts on clinical care might include: clinical outcomes and role in data collection of clinical care; 77 
public health: impact on morbidity, mortality, quality of life; services and organisations: procurements 78 
standards and best practices, service reorganisation and structural changes; costs – increased costs or savings; 79 
societal: sustainability, equity of access to products and services; legal issues: data protection, regulations; 80 
ethical issues, controversial method or highly invasive. 81 
(bi) For each of the three topics in turn, what will be the utilisation of this trend across the research 82 
and development pathway as a whole? 83 
(bii) What are the barriers for this to happen? 84 
Example barriers might include: regulatory acceptance uncertainty; costs; absence of reference standards (e.g., 85 
accepted endpoints); patient enrolment difficulties; public opinion resistance; competence in clinical setting; 86 
infrastructure (e.g., radiation, disposal of hazardous material). 87 
(c) For each of the three topics in turn, how can regulators help navigate these challenges and 88 
opportunities? 89 
Examples might include: better support in early R&D decision making; increased relationship with academia; 90 
more extended scientific advice with HTAs; more predictability with respect to regulatory engagement in 91 
clinical care translation. 92 
(ci) Are there any changes to the regulatory rules and procedures which could help? 93 
                                                          
a Committee for Medicinal Products for Human Use (CHMP), Pharmacovigilance Risk Assessment Committee 
(PRAC), Committee for Medicinal Products for Veterinary Use (CVMP), Committee for Orphan Medicinal 
Products (COMP), Committee on Herbal Medicinal Products (HMPC), Committee for Advanced Therapies 
(CAT), Paediatric Committee (PDCO), Co-ordination Group for Mutual Recognition & Decentralised Procedures 
- Human (CMDh), Scientific Advice Working Party – Human (SAWPh), Scientific Advice Working Party – 
Veterinary (SAWPv). 
b A ‘sister’ document reflecting on regulatory science and veterinary medicinal products was released at the 
same time and followed a second workshop, “EMA - Regulatory Science to 2025: Launch of Veterinary 
Stakeholder Consultation”, held at the EMA on December 6, 2018. 
(cii) What cooperation between the Agency and with other stakeholders could help? 94 
(ciii) What international collaboration could be beneficial? 95 
(civ) What competence and capacity building for the network would be beneficial? 96 
(d) Which therapeutic areas will be most impacted in the next 5 years? 97 
(e) Are there any key initiatives or consortia impacting these trends? 98 
(f) More broadly, are there any other concerns or recommendations you have for the agency? 99 
  100 
Supplementary Table 1 101 
Areas of science, technology, health and regulatory science selected for review and horizon-102 
scanning. 103 
1.  Trends in science and technology 104 
1.1 Major therapeutic areas 105 
1.1.1. Oncology 106 
1.1.2. CNS  - neurodegenerative diseases 107 
1.1.3. CNS - psychiatry 108 
1.1.4. Diabetes 109 
1.1.5. Obesity 110 
1.1.6. HIV 111 
1.1.7. Vaccines  112 
1.1.8. Immunotherapies 113 
1.1.9. Ophthalmology  114 
1.2. Gene therapy and Regenerative Medicine 115 
1.2.1. Gene therapy 116 
1.2.2. Cells and tissue-based products 117 
1.2.3. New materials 118 
1.3. Personalised medicine 119 
1.3.1. Personalised medicine  120 
1.3.2. Biomarkers 121 
1.4. Methods, technologies and other trends 122 
1.4.1. Nanotechnology 123 
1.4.2. New ‘omics (e.g., microbiomics) 124 
1.4.3. Taxonomy of disease 125 
1.4.4. Digital health and wearable technology 126 
1.4.5. Novel manufacturing and 3D printing 127 
2. Trends in the use of regulatory science tools 128 
2.1. Access pathways 129 
2.1.1. PRIME 130 
2.1.2. Adaptive pathways 131 
2.1.3. Biosimilars 132 
2.1.4. Synergies with HTAs’ activities 133 
2.1.5. Synergies with payers’ activities 134 
2.2. Non clinical methodology 135 
2.2.1. Novel non-clinical models 136 
2.2.2. Application of 3Rs in medicines development  137 
2.3. Clinical methodology 138 
2.3.1. Modelling and simulation 139 
2.3.2. Extrapolation 140 
2.3.3. Patient reported outcomes (PROs) 141 
2.3.4. New endpoints 142 
2.3.5. Bayesian methods 143 
2.3.6. Co-acting medicinal products 144 
2.3.7. Clinical trials  145 
2.4. Special populations 146 
2.4.1. Pregnancy 147 
2.4.2. Paediatric 148 
2.4.3. Geriatric 149 
2.5. Risk-benefit evaluation 150 
2.5.1. Risk-benefit project 151 
2.6. Big data and e-Health 152 
2.6.1. Big data 153 
2.6.2. Real world evidence 154 
2.6.3. Open science 155 
2.6.4. Cognitive computing  156 
2.7 Communications 157 
2.7.1. Inform social and behavioural science  158 
2.8 Pharmacoepidemiology 159 
2.8.1. Pharmacoepidemiology 160 
2.8.2. Pharmacovigilance  161 
3. Health threats 162 
3.1. Antimicrobial resistance (AMR) 163 
3.1.1 AMR  164 
3.2. Emerging Health threats 165 
3.2.1. Emerging health threats 166 
4. Environmental analysis 167 
5. International Regulatory Science cooperation 168 
169 
Supplementary Table 2  170 
Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist. 171 
Guide questions/description 
Domain 1: Research team and reflexivity 
Personal characteristics 
1. Interviewer 
Which author/s conducted the interview or focus 
group?  
PH, RG, LD, AH, MP. 
2. Credentials  What were the researcher's credentials?  MSc, PhD x 3, MD-PhD. 
3. Occupation  What was their occupation at the time of the study?  Regulators, academics. 
4. Gender  Was the researcher male or female?  3 male, 2 female. 
5. Experience and 
training  
What experience or training did the researcher have?  Mixed. 
Relationship with participants 
6. Relationship 
established  
Was a relationship established prior to study 
commencement?  
Variable. Most were 
contacted via email and 
had no relationship to the 
researchers. A few had a 
prior relationship with one 
or more researchers. 
7. Participant knowledge 
of the interviewer  
What did the participants know about the researcher?  
Participants were briefed 
on the research aims via 
email and before the 
interview commenced. 
8. Interviewer 
characteristics  
What characteristics were reported about the 
interviewer/facilitator?  
Interviewers identified as 
regulators or academics. 
Domain 2: Study design 
Theoretical framework 
9. Methodological 
orientation 
What methodological orientation was stated to 
underpin the study? 
Grounded theory. 
Participant selection 
10. Sampling How were participants selected? 
Purposive. Participants 
chosen primarily for their 
expertise, with a 
preference for those 
operating at a European 
level. 
11. Method of approach How were participants approached? 
Face-to-face, telephone, 
email. 
12. Sample size How many participants were in the study? 
70 interviews conducted, 
some with more than one 
respondent. 
13. Non-participation 
How many people refused to participate or dropped 
out? Why? 
Most dropouts were those 
who refused to reply (<60) 
Setting 
14. Setting of data 
collection 
Where were the data collected? 
Face-to-face at EMA or by 
telephone. 
15. Presence of non-
participants 
Was anyone else present besides the participants and 
researchers? 
Interested EMA colleagues 
occasionally joined. 
16. Description of 
sample 
What are the important characteristics of the sample? 
Mixed ages and genders, 
primarily European 
professionals; interviews 
held between January and 
September, 2018. 
Data collection 
17. Interview guide 
Were questions, prompts, guides provided? Was it 
pilot-tested? 
Participants were 
informed that horizon-
scanning had been 
performed, but were 
provided only with an 
introduction to this 
exercise and with the 
interview questions; no 
formal pilot testing was 
conducted. 
18. Repeat interviews 
Were repeat interviews carried out? If yes, how 
many? 
No; not applicable. 
19. Audio-visual 
recording 
Did the research use audio or visual recording to 
collect the data? 
No. 
20. Field notes 
Were field notes made during and/or after the 
interview? 
Notes were taken during 
the interviews. 
21. Duration What was the duration of the interviews? 
Semi-structured 
interviews lasted from 30 
to 100 minutes; open 
interviews from 2 to 2.5 h. 
22. Data saturation Was data saturation discussed? 
Yes, it was sought for all 
participants. 
23. Transcripts returned 
Were transcripts returned to participants for 
comment and/or correction? 
No. 
Domain 3: Analysis and findings 
Data analysis 
24. Number of data 
coders 
How many data coders coded the data? Not applicable. 
25. Description of the 
coding tree 
Was a description of the coding tree provided? See Table S1. 
26. Derivation of themes 
Were themes identified in advance or derived from 
the data? 
Areas for baseline review 
and horizon-scanning 
were selected in advance; 
the final themes were 
derived from the data and 
axial coding. 
27. Software 
What software, if applicable, was used to manage the 
data? 
Microsoft Office. 
28. Participant checking Did participants provide feedback on the findings? 
Yes, at two “EMA 
Regulatory Science to 
2025” workshops; a public 
consultation is ongoing. 
Reporting 
29. Quotations 
presented 
Were participant quotations presented to illustrate 
the themes/findings? 
No. 
30. Data and findings 
consistent 
Was there consistency between the data presented 
and the findings? 
Yes, the iterative 
methodology assured that 
this was the case. 
31. Clarity of major 
themes 
Were major themes clearly presented in the findings? 
See Table S4, strategic 
goals. 
32. Clarity of minor 
themes 
Is there a description of diverse cases or a discussion 
of minor themes? 
See Table S4, core 
recommendations. 
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Supplementary Table 3  174 
EMA Regulatory Science to 2025 – proposed strategic goals, core recommendations and 175 
underlying actions. 176 
Catalysing the integration of science & technology in drug development 
Core 
recommendations 
Underlying actions 
Support developments in 
precision medicine, 
biomarkers and ‘omics 
 Enhance early engagement with novel biomarker developers to 
facilitate regulatory qualification; 
 Address the impact of emerging ‘omics’ methods and their 
application across the development life cycle; 
 Evaluate, in collaboration with HTAs, payers and patients, the 
impact of treatment on clinical outcomes measured by biomarkers. 
Support translation of 
advanced therapy 
medicinal products 
(ATMPs) into patient 
treatments 
 Identify therapies that address unmet medical need;  
 Provide assistance with early planning, method development and 
clinical evaluation; 
 Support evidence generation, pertinent to downstream decision-
makers; 
 Address the challenges of decentralised ATMP manufacturing and 
delivery locations; 
 Raise global awareness of ATMPs to maximise knowledge sharing, 
promote data collection. 
Promote and invest in 
the PRIME scheme 
 Invest in external communication to better explain and promote 
PRIME;  
 Evaluate current capacity and identify areas for increased 
investment; 
 Shorten the time between scientific advice, clinical trials and MAA 
submission; 
 Collaborate with stakeholders to ensure efficient oversight post-
approval; 
 Leverage collaboration with patients, healthcare professionals, 
academia and international partners. 
Facilitate the 
implementation of novel 
manufacturing 
technologies 
 Recruit expertise in novel manufacturing technologies to enhance 
the assessment process; 
 Identify bottlenecks and propose modernisation of relevant 
regulations to facilitate novel manufacturing; 
 Address regulatory challenges in point-of-care manufacturing, e.g. 
concept of batch control, role of the Qualified Person;  
 Facilitate a flexible approach in application of Good Manufacturing 
Practice. 
Catalysing the integration of science & technology in drug development 
Create an integrated 
evaluation pathway for 
the assessment of 
medical devices, in vitro 
diagnostics and 
borderline products 
 Define how risk-benefit of borderline products is assessed and 
communicated;  
 Enrich expertise at the interface between medicines, medical 
devices and borderline products; 
 Facilitate the regulatory pathway between notified bodies and 
medicines’ regulators; 
 Gain insight in innovation on drug-device combination products via 
horizon scanning. 
Develop understanding 
of, and regulatory 
response to, 
nanotechnology and new 
materials in 
pharmaceuticals 
 Raise awareness of new nanomedicines and materials via the EU-
Innovation Network; 
 Generate guidance addressing PK/PD requirements and long-term 
efficacy and safety; 
 Develop guidance on regulatory pathways with device regulators 
and notified bodies. 
Diversify and integrate 
the provision of 
regulatory advice along 
the development 
continuum 
 Promote more integrated medicines development aligning scientific 
advice, clinical trials approval and Good Clinical Practice oversight;  
 Create complementary and flexible advice mechanisms to support 
innovative product development expanding multi-stakeholder 
consultation platforms; 
 Facilitate translation of innovation via a re-engineered Innovation 
Task Force and synergy with an evolving EU-Innovation Network 
platform. 
 
Driving collaborative evidence generation – improving the scientific quality of 
evaluations 
Core recommendations Underlying actions 
Leverage non-clinical 
models and 3Rs principles 
 Stimulate developers to use novel pre-clinical models, including 
those adhering to the 3Rs; 
 Re-focus the role of the 3Rs working group to support method 
qualification; 
 Encourage implementation of IT tools to exploit the added value of 
SEND  for the re-analyses of non-clinical studies to support both 
clinical trials authorisation FIM (first-in-man) and risk minimisation 
across EU. 
Foster innovation in 
clinical trials 
 Drive adoption of novel practices that facilitate clinical trial 
authorisation, GCP and HTA acceptance;  
 Critically assess the clinical value of new and emerging endpoints 
and their role in facilitating patients’ access to new medicines; 
 Work with stakeholders to encourage collaborative clinical trials; 
Catalysing the integration of science & technology in drug development 
 Collaborate with international partners in ongoing initiatives such 
as the Clinical Trial Transformation Initiative and ICH. 
Develop the regulatory 
framework for emerging 
clinical data generation 
 Develop methodology to incorporate clinical care data sources in 
regulatory decision-making; 
 Modernise the GCP regulatory oversight to enable decentralised 
models of clinical trials coupled with direct digital data accrual; 
 Develop the capability to assess complex datasets captured by 
technology such as wearables; 
 Facilitate training and understanding of healthcare professionals 
and patients to access and participate effectively in such trials. 
Expand benefit-risk 
assessment and 
communication 
 Expand the benefit-risk assessment by incorporating patient 
preferences; 
 Develop the capability to analyse Individual Patient Data to 
support decision-making; 
 Promote systematic application of structured benefit/risk 
methodology and quality assurance systems across the network; 
 Improve communication with HTAs and payers regarding 
therapeutic context, comparison vs. placebo/active-control, 
patient perspective; 
 Enhance structured benefit/risk assessment to improve 
communication to the public; 
 Incorporate academic research into evidence-based benefit-risk 
communication. 
Invest in special 
populations initiatives 
 Focus on speedy access for patient (sub-)populations in urgent 
need 
 Identify areas of highest unmet needs where clinical care data 
can supplement clinical trial data 
 Enhance multi-stakeholder advice in collaboration with 
patients, HCPs, payers and HTAs; 
 Progress implementation of the paediatric medicines action plan; 
 Progress implementation of the geriatric strategic plan; 
 Develop a strategic initiative in maternal-foetal health. 
Optimise capabilities in 
modelling, simulation and 
extrapolation 
 Enhance modelling and simulation and extrapolation use across 
the product lifecycle and leverage the outcome of EU projects; 
 Promote development and international harmonisation of methods 
and standards via a multi-stakeholder platform; 
 Increase capability and redesign the operations of relevant 
working parties to ensure wider knowledge exchange. 
Catalysing the integration of science & technology in drug development 
Exploit digital technology 
and artificial intelligence 
in decision making 
 Establish a dedicated AI test “laboratory” to explore the 
application of innovative digital technology to support data-driven 
decisions across key business processes; 
 Develop capacity and expertise across the network to engage with 
digital technology, artificial intelligence, cognitive computing, and 
their applications in the regulatory system. 
 
 
 
 
 
Advancing patient-centred access to medicines in partnership with healthcare systems 
Core recommendations Underlying actions 
Contribute to HTA’s 
preparedness and 
downstream decision 
making for innovative 
medicines 
 Ensure the evidence needed by HTAs and payers is incorporated 
early in drug development plans; 
 Enable information exchange with HTAs to support bridging from 
benefit-risk to relative effectiveness assessment; 
 Discuss with HTAs guidance and methodologies for evidence 
generation and review; 
 Contribute to the identification of priorities for HTA; 
 Monitor the impact of decision-maker engagement through reviews 
of product-specific experience. 
Bridge from evaluation to 
access through 
collaboration with payers 
 Contribute to the preparedness of healthcare systems by creating 
opportunities for collaboration on horizon scanning; 
 Enable involvement of payers’ requirements in the prospective 
discussion of evidence generation plans; 
 Clarify the treatment-eligible patient population included in the 
labelling, and its scientific rationale; 
 Participate in discussions clarifying the concept of unmet medical 
need. 
Reinforce patient 
relevance in evidence 
generation 
 Enhance patient involvement in EMA scientific committees; 
 Coordinate Agency’s approach to patient reported outcomes 
(PROs). Update relevant clinical guidelines to include reference to 
PROs addressing study objectives, design and analysis; 
 While validating PROs, address patients’ needs and leverage 
patients’ expertise;  
Catalysing the integration of science & technology in drug development 
 Co-develop with HTAs a core health-related quality-of-life PRO to 
implement in trials and to bridge the gap with comparative 
effectiveness assessment; 
 Explore additional methodologies to gather and use patient data 
from the wider patient community during benefit-risk evaluation. 
Promote use of high-
quality real-world data 
(RWD) in decision making 
 Create a sustainable, quality assured, flexible framework delivering 
rapid access to and analysis of representative, longitudinal RWD 
throughout a product’s lifecycle; 
 Develop a capacity that will enable the Agency to rapidly and 
securely access and analyse large amounts of healthcare data; 
 Accelerate the implementation of a learning regulatory system 
based on electronic health records and other routinely collected 
clinical care data (including RWD). 
Develop network 
competence and specialist 
collaborations to engage 
with big data 
 Implement the core recommendations emerging from the HMA-
EMA Joint Big Data Taskforce addressing areas such as 
harmonisation of data standards, characterisation of data quality, 
and provision of regulatory guidance as to acceptability of 
evidence; 
 Engage proactively with new stakeholders relevant to the big data 
landscape; 
 Invest in capacity building across the network to acquire new skills 
to engage with these emerging areas. 
Deliver improved product 
information in electronic 
format (ePI) 
 Enable real-time interactivity within the Summary of Product 
Characteristics and Patient Leaflet; 
 In conjunction with healthcare providers and patients, develop a 
strategic plan to deliver the ePI programme; 
 Enable the reuse of structured medicinal product information by 
third parties through development of a standardised interface; 
 Address the need for PI content improvements identified in the EC 
report (COM(2017) 135 final), such as package leaflet layout and 
readability. 
Promote the availability 
and support uptake of 
biosimilars in healthcare 
systems 
 Further develop strategic communication campaigns to healthcare 
providers and patient organisations to reinforce trust and 
confidence; 
 Enhance training of non-EU regulators in the evaluation of 
biosimilars with extension to all therapeutic areas; 
 Address regulatory challenges in manufacturing e.g., statistical 
assessment of CQAs in the comparability exercise and the 
evolution of multisource biologicals/biosimilars. 
Further develop external 
engagement and 
communications to 
 Develop content strategy, particularly in key public health areas 
and hot topics in regulatory science 
Catalysing the integration of science & technology in drug development 
promote trust and 
confidence in the EU 
regulatory system 
 Enhance professional outreach through scientific publications & 
conferences 
 Proactive approach to key public-health areas (e.g. vaccines) 
 Improved communications for patients, healthcare professionals, 
HTAs and payers; 
 Develop more targeted and evidence-based communication 
facilitated by updated web content and format. 
 
Addressing emerging health threats and availability/therapeutic challenges 
Core recommendations Underlying actions 
Implement EMA’s health 
threats plan, ring-fence 
resources and refine 
preparedness approaches 
 Coordinate scientific and regulatory activities within the EU 
network; 
 Evaluate preparedness for emerging pathogens and ‘disease X’; 
 Coordinate discussions with the EU network, international partners 
and stakeholders on the identification, development, authorisation 
and post-authorisation follow-up of relevant medicinal products; 
 Effective and timely communication to healthcare professionals, 
the public and regulatory partners. 
Continue to support 
development of new 
antibacterial agents and 
their alternatives 
 Evolve regulatory guidance and support alternative approaches to 
new antibacterial drug development and innovative approaches for 
prevention and treatment of infections; 
 Support initiatives, such as the clinical trials network, to facilitate 
and accelerate clinical development; 
 Encourage new business models that provide “pull” incentives 
beyond the current “funding research” strategy in the EU; 
 In collaboration with HTAs and payers, define the evidence 
requirements for new antibacterial medicines; 
 Support the development and application of rapid diagnostic tools. 
Promote global 
cooperation to anticipate 
and address supply 
problems 
 Build on deliverables from the work plan of the HMA/EMA Task 
Force on availability of authorised medicines; 
 Explore mechanisms to increase manufacturing capacity in Europe 
and internationally; 
 Enhance collaboration with WHO in the area of supply disruptions 
due to manufacturing quality issues; 
 Promote greater knowledge exchange with international 
stakeholders on shortages due to quality/manufacturing issues; 
Catalysing the integration of science & technology in drug development 
 Continue to engage with healthcare professionals, patients and 
consumers organisations and the industry to address the causes 
and consequences of lack of medicines’ availability; 
 Support international harmonisation of regulatory science 
standards for generic medicines addressing bioequivalence, 
waivers and modelling. 
Support innovative 
approaches to the 
development, approval 
and post-authorisation 
monitoring of vaccines 
 Advance methods/tools (e.g. biomarkers) to characterise immune 
response and to support definition of vaccine quality attributes; 
 Examine innovative clinical trial approaches to expedite vaccine 
development; 
 Engage with public health authorities and NITAGs  to better inform 
vaccine decisions;  
 Establish a platform for EU benefit-risk (B/R) monitoring of 
vaccines post-approval; 
 Communicate proactively with key stakeholders on B/R using 
evidence-based tools to tackle vaccine hesitancy. 
Support the development 
and implementation of a 
repurposing framework 
 Enhance regulatory advice on evidence generation and MAA 
submission; 
 Frame suitability of third party data-pooling, relevant RWD and 
historical non-clinical datasets; 
 Translate experience with EMA’s registry pilot to guide RWD 
collection; 
 Explore utility of low-intervention clinical trials for evidence 
generation. 
 
Enabling and leveraging research and innovation in regulatory science 
Core recommendations Underlying actions 
Develop network-led 
partnerships with 
academia to undertake 
fundamental research in 
strategic areas of 
regulatory science 
 Identify, in consultation with academia and relevant stakeholders, 
fundamental research topics in strategic areas of regulatory 
science (such as PROs, omics-based diagnostics, drug-device 
combinations, modelling and simulation, Big Data, and artificial 
intelligence); 
 Proactively engage with DG Research & Innovation, DG-SANTE, 
IMI and Member State funding agencies to propose and issue calls 
to establish research collaborations. 
Leverage collaborations 
between academia and 
network scientists to 
address rapidly emerging 
 Ring-fence EMA funding to address rapidly-emerging regulatory 
science research questions (such as diagnostics, precision 
medicine, distributed manufacturing, wearable devices, drug re-
purposing); 
Catalysing the integration of science & technology in drug development 
regulatory science 
research questions 
 Ensure close interaction between network scientists and academia 
to deliver tangible impact through translation of this applied 
research into new drug products and regulatory tools; 
 Actively engage, through these applied projects, in training early-
career researchers in regulatory science (e.g., via placements 
within the network). 
Identify and enable access 
to the best expertise 
across Europe and 
internationally 
 Invest in a knowledge management system to track innovation, 
share information, enable linkages and create new insights across 
the product lifecycle; 
 Facilitate more flexible access to global expertise in regulatory 
science and increasingly specialised and new areas of innovation. 
Disseminate and 
exchange knowledge, 
expertise and innovation 
across the network and to 
its stakeholders 
 Engage with academia to develop regulatory training modules, 
including describing innovation of new medicines and their 
progression from laboratory to patient; 
 Conduct horizon scanning in key areas of innovation via 
collaborations with academia, the EU-Innovation Network and 
ICMRA; 
 Drive a data-sharing culture to foster open science which is 
mutually beneficial for all stakeholders. 
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